Anti-Complement C5b-9 Antibody (aE11)
Our mouse Complement C5b-9 monoclonal antibody from Antibodies Incorporated is produced from clone aE11. It detects horse, human, non-human primate, and pig Complement C5b-9 and is Protein A or Protein G purified. Works in ELISA, IF, IHC, WB.
Immunohistochemistry detection of Complement C5b-9 in human tonsil tissue using Anti-Complement C5b-9 Antibody (Cat. DIA 011-01-010). Tissue was mounted and pariffin fixed. Heat induced antigen retrieval was performed using citrate buffer, heated, and then blocked. After washing, the primary antibody (Cat. DIA 011-01-010) was incubated with the sample at a dilution of 1:10. Vascular endothelia and dendritic cells of germinal center have strong and intensive label.
Click on image to zoom
SKU: DIA 011-01-010
Ships: 1-2 business days
Product Details
Complement C5b-9
C5b-9 is also known as the terminal complement complex (TCC). The TCC consists of C5b, C6, C7, C8 and C9 and forms the membrane attack complex (MAC) as well as the non-lytic fluid-phase SC5b-9 complex (with protein S). The MAC forms channels in target cell membranes leading to cell lysis by osmotic leakage. The complexes contain neoantigens that are absent from the individual native components from which they are formed and DIA 011-01 is directed against a neoepitope exposed on C9 when incorporated into the TCC.
Protein A or Protein G purified
1 mg/mL ±15%
Monoclonal
aE11
IgG2a/k
ELISA, IF, IHC, WB
Mouse
C5, C6, C7, C8, C9
Purified C5b-9
Human
Horse, Human, Monkey
2-8°C without exposure to light
Liquid
BSA free
0.01 M phosphate buffer, pH 7.4, containing 0.15 M NaCl, 0,09% sodium azide
DIA 011-01 is well suited for quantifying TCC in ELISA. (2,3) DIA 011-01 is not recommended for Western blotting as the epitope is destroyed during the process. (4) TCC in various tissues by immunohistochemistry (frozen and paraffin sections). (1, 2, 4)
Unconjugated
DIA 011-01 binds both membrane-bound MAC (active) and fluid-phase SC5b-9 complexes (inactive). (1) DIA 011-01 binds to a neoepitope exposed on C9
These antibodies are to be used as research laboratory reagents and are not for use as diagnostic or therapeutic reagents in humans.
United States
24 months from date of receipt
C5; CPAMD4; Complement C5; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4; Cleaved into: Complement C5 beta chain; Complement C5 alpha chain; C5a anaphylatoxin; Complement C5b; Complement C5 alpha' chain; C5D; C5a; C5b; ECLZB; anaphylatoxin C5a analog; complement component 5; prepro-C5
Precursor of the C5a anaphylatoxin and complement C5b components of the complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:12878586, PubMed:18204047, PubMed:30643019, PubMed:6554279). Activated downstream of classical, alternative, lectin and GZMK complement pathways (PubMed:12878586, PubMed:18204047, PubMed:30643019, PubMed:39914456, PubMed:39814882, PubMed:6554279). {ECO:0000269|PubMed:12878586, ECO:0000269|PubMed:18204047, ECO:0000269|PubMed:30643019, ECO:0000269|PubMed:39814882, ECO:0000269|PubMed:39914456, ECO:0000269|PubMed:6554279}.; [Complement C5b]: Component of the membrane attack complex (MAC), a multiprotein complex activated by the complement cascade, which inserts into a target cell membrane and forms a pore, leading to target cell membrane rupture and cell lysis (PubMed:26841837, PubMed:27052168, PubMed:30552328, PubMed:30643019). Complement C5b is generated following cleavage by C5 convertase and initiates formation of the MAC complex: C5b binds sequentially C6, C7, C8 and multiple copies of the pore-forming subunit C9 (PubMed:30552328, PubMed:30643019). During MAC complex assembly, the C5b6 subcomplex, composed of complement C5b and C6, associates with the outer leaflet of target cell membrane, reducing the energy for membrane bending (PubMed:30552328, PubMed:32569291). {ECO:0000269|PubMed:26841837, ECO:0000269|PubMed:27052168, ECO:0000269|PubMed:30552328, ECO:0000269|PubMed:30643019, ECO:0000269|PubMed:32569291}.; [C5a anaphylatoxin]: Mediator of local inflammatory process released following cleavage by C5 convertase (PubMed:8182049, PubMed:9553099). Acts by binding to its receptor (C5AR1 or C5AR2), activating G protein-coupled receptor signaling and inducing a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes (PubMed:36806352, PubMed:37852260, PubMed:37169960, PubMed:8182049, PubMed:9553099). C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation (PubMed:342601, PubMed:37852260, PubMed:37169960, PubMed:5765461, PubMed:8182049, PubMed:9553099). {ECO:0000269|PubMed:342601, ECO:0000269|PubMed:36806352, ECO:0000269|PubMed:37169960, ECO:0000269|PubMed:37852260, ECO:0000269|PubMed:5765461, ECO:0000269|PubMed:8182049, ECO:0000269|PubMed:9553099}.
727
Shipped on ice packs

